Videos

 
“High Interest Rate Depends On CPI Inflation, CAD, Dollar”

“High Interest Rate Depends On CPI Inflation, CAD, Dollar”

July 22: “If India runs negative real interest rate and has a large current account deficit, it will discourage foreign investors,” says Chetan Ahya, MD & Asia Pacific Economist at Morgan Stanley. He also reviews the impact of RBI liquidity tightening measures on growth and monetary policy.

Decoding RBI’s Toolkit With Morgan Stanley

Decoding RBI’s Toolkit With Morgan Stanley

July 22: The Street is not very happy with Reserve Bank of India’s moves to steady the rupee but Chetan Ahya, MD & Asia Pacific Economist at Morgan Stanley, says that the central bank is trying to convey that there is a limit to which it can allow rupee depreciation.

“Banks Financially Strong To Bear NPAs”

“Banks Financially Strong To Bear NPAs”

July 22: FICCI President Naina Lal Kidwai says, “Though NPAs coming off lows is good, we expect an increase in NPAs due to slowdown.” The twin deficits, especially the current account, and inflation remain the key economic concerns, she adds.

Getting Project Approvals Upfront Is Key: FICCI

Getting Project Approvals Upfront Is Key: FICCI

July 22: FICCI President Naina Lal Kidwai says, “Many power and oil & gas projects have been cleared, but there is a need to get cleared projects operationalised.” She tells Bloomberg TV India that states play a key role in project approvals.

Welcome Govt Moves On FDI Caps: FICCI

Welcome Govt Moves On FDI Caps: FICCI

July 22: “Given the fact that telecom is a debt-ridden sector; FDI move is welcome. There is a strong prospect of increased investment coming into telecom,” says Naina Lal Kidwai, the President of FICCI, adding that insurance will also benefit from the FDI cap hike.

RBI's Aim To Curb Re Fall Achieved: FICCI

RBI's Aim To Curb Re Fall Achieved: FICCI

July 22: “Though immediate effect of RBI move is on liquidity, we are fortunate that the central bank did not hike the repo rate,” FICCI President Naina Lal Kidwai says, while speaking about Corporate India’s take on RBI measures to tighten money rates.

Dr. Reddy's Labs - Following The Vision

Dr. Reddy's Labs - Following The Vision

GK Prasad discusses Dr. Anji Reddy’s vision of discovering new drugs & the state of the volatile Rupee in this segment of Inside India’s Best Known Companies.

Making It Big - The Growth Of Dr.Reddy's Labs

Making It Big - The Growth Of Dr.Reddy's Labs

Dr.Reddy’s Labs’ GK Prasad speaks about the early years and the evolution of the company. Listen to him speak to Bloomberg TV India’s Mini Menon about the setbacks that the company faced.

Dr.Reddy's Labs - The Growth Drivers

Dr.Reddy's Labs - The Growth Drivers

GK Prasad, Dr.Reddy’s Labs’ MD speaks to Bloomberg TV India’s Mini Menon about the growth drivers that will help the pharma giant grow. Also, listen to Accenture India’s Sriram Srinivasan analyse the potential for the Indian pharma industry.

Indian Markets

 
  • SENSEX

    35,286.74 261.52   (-0.74 %)
  • NIFTY

    10,710.45 89.40   (-0.83 %)
sensex-box-shadowimg

Global Markets

 

Stocks In News

 

BHARAT 22 ETF

ONGC
IOC
BPCL
SBI
Bank of Baroda
Indian Bank
Coal India
NALCO
BEL
Engineers India
NBCC
NTPC
NHPC
SJVNL
GAIL
Power Grid
NLC India

L&T
ITC
Axis Bank

BHARAT 22 ETF

Exposure

 

Pvt Sector 39%


PSU Stocks 61%

BHARAT 22 ETF

Second tranche to open today, 2.5% discount across categories

Government looking to raise up to Rs 8,400 Cr

Consists of stocks from six sectors

ASHOK LEYLAND

Hinduja Leyland Finance files for IPO

Hinduja Leyland Finance IPO to raise Rs 500 Cr

TITAN


Sells shares of Titan Time products unit to Danlaw Tech

To receive Rs 18.5 Cr from unit
Sale

AVIATION IN FOCUS

Airports run out of slots, parking space

Delhi, Mumbai offering slots between 11 P.M & 5 A.M only

Pune & Goa not offering any slots for new flights

Bengaluru, Chennai & Kolkata don't have any slots in peak time

GLENMARK PHARMA

USFDA nod for Atovaquone & Proguanil Hydrochloride tablets

First supplemental ANDA from U.S. MFG facility

U.S. Facility to provide foundation for future product approvals

U.S. Facility peak capacity of 300-400 Mn tablets per year

Has invested more than $100 Mn into the U.S. Facility

twitter @BTVI